Cite
Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.
MLA
Broeckel, Rebecca, et al. “Therapeutic Administration of a Recombinant Human Monoclonal Antibody Reduces the Severity of Chikungunya Virus Disease in Rhesus Macaques.” PLoS Neglected Tropical Diseases, vol. 11, no. 6, June 2017, pp. 1–25. EBSCOhost, https://doi.org/10.1371/journal.pntd.0005637.
APA
Broeckel, R., Fox, J. M., Haese, N., Kreklywich, C. N., Sukulpovi-Petty, S., Legasse, A., Smith, P. P., Denton, M., Corvey, C., Krishnan, S., Colgin, L. M. A., Ducore, R. M., Lewis, A. D., Axthelm, M. K., Mandron, M., Cortez, P., Rothblatt, J., Rao, E., Focken, I., & Carter, K. (2017). Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Neglected Tropical Diseases, 11(6), 1–25. https://doi.org/10.1371/journal.pntd.0005637
Chicago
Broeckel, Rebecca, Julie M. Fox, Nicole Haese, Craig N. Kreklywich, Soila Sukulpovi-Petty, Alfred Legasse, Patricia P. Smith, et al. 2017. “Therapeutic Administration of a Recombinant Human Monoclonal Antibody Reduces the Severity of Chikungunya Virus Disease in Rhesus Macaques.” PLoS Neglected Tropical Diseases 11 (6): 1–25. doi:10.1371/journal.pntd.0005637.